Short Interest in CalciMedica Inc. (NASDAQ:CALC) Rises By 497.8%

CalciMedica Inc. (NASDAQ:CALC) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 1,651,945 shares, a growth of 497.8% from the June 15th total of 276,326 shares. Currently, 17.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 6,188,729 shares, the short-interest ratio is presently 0.3 days.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CalciMedica in a research note on Tuesday. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CalciMedica currently has an average rating of “Hold” and a consensus target price of $10.00.

Insider Activity at CalciMedica

In other CalciMedica news, Director Fred A. Middleton purchased 248,972 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were purchased at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the purchase, the director owned 1,063,272 shares in the company, valued at approximately $850,617.60. This represents a 30.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 41.55% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Cetera Investment Advisers lifted its holdings in CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares during the last quarter. 180 Wealth Advisors LLC increased its stake in CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after acquiring an additional 94,650 shares during the last quarter. Renaissance Technologies LLC increased its stake in CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after acquiring an additional 39,775 shares during the last quarter. Jane Street Group LLC purchased a new stake in CalciMedica in the fourth quarter valued at $127,000. Finally, Envestnet Asset Management Inc. raised its position in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the period.

CalciMedica Stock Down 2.1%

NASDAQ:CALC traded down $0.02 on Friday, hitting $0.93. The stock had a trading volume of 178,067 shares, compared to its average volume of 3,401,162. The company has a fifty day moving average price of $0.79 and a two-hundred day moving average price of $1.67. CalciMedica has a 1-year low of $0.46 and a 1-year high of $7.20. The stock has a market cap of $14.69 million, a price-to-earnings ratio of -0.71 and a beta of 0.89.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.